

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 6, 2015

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation)

001-12421

(Commission File Number)

87-0565309

(IRS Employer Identification
Number)

75 West Center Street
Provo, Utah 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2015, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2015, and certain other information. A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.

The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

The press release furnished herewith in Exhibit 99.1 may contain non-GAAP financial measures. Management believes non-GAAP financial measures assist management and investors in evaluating and comparing period-to-period results and projections in a more meaningful and consistent manner.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit.

99.1 Nu Skin Enterprises' press release dated August 6, 2015, regarding financial results for the three- and six-month periods ended June 30, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.
(Registrant)

/s/ Ritch Wood
Ritch Wood
Chief Financial Officer

Date: August 6, 2015

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	Nu Skin Enterprises' press release dated August 6, 2015, regarding financial results for the three- and six-month periods ended June 30, 2015.



FOR IMMEDIATE RELEASE

CONTACTS:

Investors — Scott Pond (801) 345-2657, spond@nuskin.com

Media — Kara Schneck (801) 345-2116, kschneck@nuskin.com

NU SKIN ENTERPRISES REPORTS SECOND-QUARTER 2015 RESULTS

PROVO, Utah — Aug. 6, 2015 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced second-quarter results with revenue of \$560.2 million compared to \$650.0 million in the prior-year period. Revenue in the quarter was negatively impacted 7 percent by foreign currency fluctuations. Revenue in the second quarter of 2014 included \$76 million in limited-time offer product sales, while there were no significant limited-time offers during the second quarter of 2015. Earnings per share for the quarter were \$0.75, compared to \$0.32 in the prior-year period which included a \$50 million inventory write-down and a \$25 million foreign currency charge related to Venezuela.

"We are pleased the business performed at the high end of our expectations for the second quarter," said Truman Hunt, president and chief executive officer. "Additionally, we are encouraged by growth in the number of sales leaders sequentially, including a 19 percent increase in sales leaders in Mainland China. We believe that this trend signals growing sales leader energy as we build toward the introduction of our new ageLOC products in the second half of the year.

-more-

"Additionally, our financial performance and strong cash flow enabled us to repurchase approximately \$50 million of shares in the second quarter. Overall, we are pleased with the direction of the business and continue to anticipate a return to revenue growth in the second half of the year."

Regional Results

The company's regional revenue results for the three-month periods ended June 30 are presented in the following table.

	<u>2015</u>	<u>2014</u>	<u>% Change</u>	<u>Constant Currency % Change</u>
Greater China	\$ 200,136	\$ 229,869	(13%)	(13%)
North Asia	172,943	195,995	(12%)	(2%)
Americas	83,468	89,911	(7%)	5%
South Asia/Pacific	68,023	81,653	(17%)	(9%)
EMEA	<u>35,639</u>	<u>52,599</u>	(32%)	(16%)
Total	<u>\$ 560,209</u>	<u>\$ 650,027</u>	(14%)	(7%)

The company's regional revenue results for the six-month periods ended June 30 are presented in the following table.

	<u>2015</u>	<u>2014</u>	<u>% Change</u>	<u>Constant Currency % Change</u>
Greater China	\$ 387,503	\$ 508,798	(24%)	(23%)
North Asia	345,009	391,456	(12%)	(4%)
Americas	163,340	169,820	(4%)	12%
South Asia/Pacific	138,840	152,847	(9%)	(2%)
EMEA	<u>68,849</u>	<u>98,167</u>	(30%)	(13%)
Total	<u>\$ 1,103,541</u>	<u>\$ 1,321,088</u>	(16%)	(10%)

The company's regional actives and sales leaders statistics are presented in the following table.

	<u>As of June 30, 2015</u>		<u>As of June 30, 2014</u>		<u>% Increase (Decrease)</u>	
	<u>Actives</u>	<u>Sales Leaders</u>	<u>Actives</u>	<u>Sales Leaders</u>	<u>Actives</u>	<u>Sales Leaders</u>
Greater China	215,000	25,956	256,000	26,192	(16.0%)	(0.9%)
North Asia	387,000	16,991	393,000	17,186	(1.5%)	(1.1%)
Americas	180,000	7,892	189,000	7,627	(4.8%)	3.5%
South Asia/Pacific	120,000	7,279	120,000	7,450	—	(2.3%)
EMEA	<u>113,000</u>	<u>4,042</u>	<u>121,000</u>	<u>4,468</u>	(6.6%)	(9.5%)
Total	<u>1,015,000</u>	<u>62,160</u>	<u>1,079,000</u>	<u>62,923</u>	(5.9%)	(1.2%)

-more-

"Actives" are persons who purchased products directly from the company during the previous three months.

"Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

Operational Performance

The company's operating margin for the quarter was 12.8 percent, compared to 8.4 percent in the second quarter of 2014. Gross margin during the quarter was 80.3 percent, versus 76.0 percent in the prior-year period. Last year's gross margin was unusually low due to the inventory write-down. Selling expenses were 42.7 percent of sales in the second quarter, compared to 43.6 percent in the prior-year period. General and administrative expenses were 24.8 percent of sales compared to 24.0 percent in the prior-year period. The company's effective income tax rate for the quarter was 35.3 percent, compared to 42.0 percent in the prior year. Last year's tax rate was abnormally high due to the tax impact of a foreign currency charge related to Venezuela. Cash and current investments at the end of the quarter were \$303.9 million and debt was \$252.1 million. Dividend payments during the quarter were \$20.5 million. Cash flow from operations for the quarter was \$85.4 million, and the company repurchased \$49.6 million of its outstanding shares.

Outlook

"Sales leader enthusiasm continues to build for our upcoming limited-time product launches that include ageLOC Youth, our most advanced anti-aging supplement, as well as ageLOC Me, a unique anti-aging skin care system that enables consumers to personalize a daily regimen based on individual preferences and skin care needs," said Hunt. "These new ageLOC products will be highlighted at our global sales leader convention in early October, and we anticipate they will help drive healthy year-over-year growth in the second half of 2015. We expect this momentum to continue as we begin to roll these products out on a full-time basis in 2016.

"We are also pleased with our progress in several key markets, particularly Mainland China, where we generated healthy sequential growth in both sales leaders and revenue. In the Greater China region, we will be rolling out our ageLOC Essentials line of cosmetic oils in the third quarter. As we move closer to our product launches, we expect positive trends to continue in our global sales force, and also anticipate growth in our active consumer base," concluded Hunt.

-more-

"We project second-half local-currency revenue growth of approximately 15 percent," said Ritch Wood, chief financial officer. "Our prior guidance anticipated a negative foreign currency impact of 7 percent in the third and fourth quarters. We now project a negative impact of 10 to 11 percent. Given this impact, we anticipate third-quarter revenue will be in the \$600 to \$620 million range with earnings per share of \$0.96 to \$1.00. We anticipate annual revenue to be in the \$2.40 to \$2.44 billion range, with earnings per share of \$3.47 to \$3.55 which includes a \$0.12 expense associated with the Venezuela foreign currency charge in the first quarter of this year. Excluding this charge, earnings guidance would be in the range of \$3.59 to \$3.67. Including currency impact, this guidance reflects second-half reported revenue growth of between 5 and 6 percent," concluded Wood.

The Nu Skin management team will host a conference call with the investment community on Aug. 6, 2015, at 5 p.m. (EDT). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Aug. 21, 2015.

About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the ageLOC® line of products including ageLOC® Tru Face® Essence Ultra firming serum, the ageLOC® TR90® weight management and body shaping system, ageLOC® R² nutritional supplement, and ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and is traded on the New York Stock Exchange under the symbol "NUS." More information is available at <http://www.nuskin.com>.

-more-

Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, new product introductions, sales force and consumer base; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- any failure of current or planned initiatives or products to generate interest among our sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- risk that direct selling laws and regulations in any of our markets, including the United States and China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if we over-forecast demand for a product or change our planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- unpredictable economic conditions and events globally;
- any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

-more-

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
For the Second Quarters Ended June 30, 2015 and 2014
(in thousands, except per share amounts)

	<u>2015</u>	<u>2014</u>
Revenue	\$ 560,209	\$ 650,027
Cost of sales	<u>110,263</u>	<u>156,010</u>
Gross profit	<u>449,946</u>	<u>494,017</u>
Operating expenses:		
Selling expenses	239,449	283,575
General and administrative expenses	<u>138,696</u>	<u>155,705</u>
Total operating expenses	<u>378,145</u>	<u>439,280</u>
Operating income	71,801	54,737
Other income (expense), net	<u>(2,758)</u>	<u>(21,119)</u>
Income before provision for income taxes	69,043	33,618
Provision for income taxes	<u>24,386</u>	<u>14,111</u>
Net income	<u>\$ 44,657</u>	<u>\$ 19,507</u>
Net income per share:		
Basic	\$ 0.76	\$ 0.33
Diluted	\$ 0.75	\$ 0.32
Weighted average common shares outstanding:		
Basic	58,506	59,052
Diluted	59,713	61,118

-more-

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
For the Six-Month Periods Ended June 30, 2015 and 2014
 (in thousands, except per share amounts)

	2015	2014
Revenue	\$ 1,103,541	\$ 1,321,088
Cost of sales	215,318	262,654
Gross profit	888,223	1,058,434
Operating expenses:		
Selling expenses	473,454	596,676
General and administrative expenses	274,322	305,824
Total operating expenses	747,776	902,500
Operating income	140,447	155,934
Other income (expense), net	(15,026)	(38,627)
Income before provision for income taxes	125,421	117,307
Provision for income taxes	44,482	42,946
Net income	\$ 80,939	\$ 74,361
Net income per share:		
Basic	\$ 1.38	\$ 1.26
Diluted	\$ 1.35	\$ 1.22
Weighted average common shares outstanding:		
Basic	58,747	58,961
Diluted	59,994	61,177

-more-

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
 (in thousands)

	<u>June 30,</u> <u>2015</u>	<u>December 31,</u> <u>2014</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 292,414	\$ 288,415
Current investments	11,518	11,793
Accounts receivable	43,543	35,834
Inventories, net	305,027	338,491
Prepaid expenses and other	<u>155,205</u>	<u>160,134</u>
	807,707	834,667
Property and equipment, net	473,216	464,783
Goodwill	112,446	112,446
Other intangible assets, net	70,900	75,062
Other assets	<u>138,351</u>	<u>127,476</u>
Total assets	<u>\$ 1,602,620</u>	<u>\$ 1,614,434</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 39,464	\$ 34,712
Accrued expenses	306,319	300,847
Current portion of long-term debt	<u>74,966</u>	<u>82,770</u>
	420,749	418,329
Long-term debt	177,178	164,567
Other liabilities	<u>100,808</u>	<u>89,100</u>
Total liabilities	<u>698,735</u>	<u>671,996</u>
Stockholders' equity:		
Class A common stock	91	91
Additional paid-in capital	418,243	414,394
Treasury stock, at cost	(933,040)	(862,608)
Accumulated other comprehensive loss	(63,251)	(51,521)
Retained earnings	<u>1,481,842</u>	<u>1,442,082</u>
	903,885	942,438
Total liabilities and stockholders' equity	<u>\$ 1,602,620</u>	<u>\$ 1,614,434</u>